Nphp4 and Bbs5 are required for ciliary mediated cell signaling events that regulate cardiac development in the mouse

Nphp4 和 Bbs5 是调节小鼠心脏发育的纤毛介导的细胞信号传导事件所必需的

基本信息

  • 批准号:
    9906036
  • 负责人:
  • 金额:
    $ 3.65万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-03-01 至 2023-02-28
  • 项目状态:
    已结题

项目摘要

Project Abstract: ( 30 lines maximum) The primary cilium is a microtubule-based structure that protrudes from the surface of nearly every cell type in the mammalian body. At the base of the cilium is a complex of proteins forming the transition zone (TZ), a diffusion barrier separating the cilium from the cytoplasm. Correct separation of these domains is important for establishing the cilium as a specialized sensory and signaling compartment. How proteins are transported into and out of the cilium across the TZ is poorly understood but appears to involve a complex of eight proteins that constitute the BBSome. Mutations disrupting these structures, and others related to primary cilia result in a spectrum of human diseases collectively called ciliopathies. These disruptions manifest in a plethora of physiological and developmental disorders that are highly variable. The primary goals of my study are to elucidate the mechanism by which the TZ and BBSome collaboratively work to regulate primary cilium functions important for normal cardiac development in mice, and to elucidate ciliary related regulation of Congenital Heart Defects (CHD). In the United States, CHD is the leading cause of birth-defect associated illness and death in infants. Studies from a genetic screen orchestrated to identify CHD-related genes identified 34 that were associated with the cilium out of 61 total CHD associated genes. Furthermore, studies that have specifically removed the primary cilium from the developing heart have reported CHD related abnormalities. These data strongly support the premise of this application that the primary cilium plays an extensive, but not yet understood, role in CHD pathogenesis. We have previously identified identified genetic interactions between the TZ component, Nphp4, and the BBSome component, Bbs5, through studies in C. elegans. The goal of my study is to extend these studies into a mammalian system and to define the contribution that Nphp4 and Bbs5 have during heart development. My preliminary data indicate that Nphp4; Bbs5 double mutant mice are embryonic lethal between embryonic day 16.5 and birth, while each of the single mutants is viable. My preliminary studies indicate that the lethality is likely associated with critical events disrupting cardiac development. Based on my preliminary data, I hypothesize that genetic interactions between Nphp4 and Bbs5 are necessary for proper cilia function and cardiovascular development, likely through altered regulation of transport of proteins into and out of the cilium. Thus, the data generated from this study will provide critical new understanding of how the primary cilium regulates early cardiac development and how cilia dysfunction contributes to CHD.
项目摘要:(最多30行) 初级纤毛是一种基于微管的结构,从几乎每种细胞类型的表面突出, 哺乳动物的身体。在纤毛的基部是形成过渡区(TZ)的蛋白质复合物, 将纤毛与细胞质分开的扩散屏障。正确分离这些结构域对于 建立纤毛作为专门的感觉和信号室。蛋白质是如何被运输到 而在TZ上的纤毛外,人们对这种现象知之甚少,但似乎涉及一种由八种蛋白质组成的复合体, 构成了BBSome。破坏这些结构的突变,以及其他与初级纤毛相关的突变, 统称为纤毛病的人类疾病谱。这些破坏表现在大量的 高度可变的生理和发育障碍。我研究的主要目标是 阐明TZ和BBSome协同调节初级纤毛的机制 功能的重要性,正常的心脏发育的小鼠,并阐明纤毛相关的调节, 先天性心脏病(CHD)。在美国,CHD是出生缺陷相关的主要原因, 婴儿的疾病和死亡。通过基因筛选确定CHD相关基因的研究 在61个CHD相关基因中,有34个与纤毛相关。此外,研究表明, 特别是从发育中的心脏中去除初级纤毛的研究报告了CHD相关的异常。 这些数据有力地支持了这一应用的前提,即初级纤毛起着广泛的作用,但不是 尚未了解的在CHD发病机制中的作用。我们以前已经确定了遗传相互作用 通过对C.优美的的 我的研究目标是将这些研究扩展到哺乳动物系统,并确定Nphp 4的贡献 和Bbs 5在心脏发育期间具有。我的初步数据表明,Nphp 4; Bbs 5双突变小鼠 在胚胎16.5天和出生之间是胚胎致死的,而每个单一突变体都是可行的。我 初步研究表明,致死性可能与严重事件有关, 发展根据我的初步数据,我假设Nphp 4和Bbs 5之间的遗传相互作用 是正常纤毛功能和心血管发育所必需的,可能是通过改变 蛋白质进出纤毛的运输。因此,这项研究产生的数据将提供关键的新的 了解初级纤毛如何调节早期心脏发育和纤毛功能障碍 导致CHD。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Melissa R Bentley其他文献

Melissa R Bentley的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Melissa R Bentley', 18)}}的其他基金

Nphp4 and Bbs5 are required for ciliary mediated cell signaling events that regulate cardiac development in the mouse
Nphp4 和 Bbs5 是调节小鼠心脏发育的纤毛介导的细胞信号传导事件所必需的
  • 批准号:
    10116177
  • 财政年份:
    2020
  • 资助金额:
    $ 3.65万
  • 项目类别:

相似国自然基金

Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
  • 批准号:
    24K12256
  • 财政年份:
    2024
  • 资助金额:
    $ 3.65万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
  • 批准号:
    24K19176
  • 财政年份:
    2024
  • 资助金额:
    $ 3.65万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
  • 批准号:
    10578068
  • 财政年份:
    2023
  • 资助金额:
    $ 3.65万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 3.65万
  • 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
  • 批准号:
    10650593
  • 财政年份:
    2023
  • 资助金额:
    $ 3.65万
  • 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
  • 批准号:
    10649275
  • 财政年份:
    2023
  • 资助金额:
    $ 3.65万
  • 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
  • 批准号:
    10784209
  • 财政年份:
    2023
  • 资助金额:
    $ 3.65万
  • 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
  • 批准号:
    10734158
  • 财政年份:
    2023
  • 资助金额:
    $ 3.65万
  • 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
  • 批准号:
    10580259
  • 财政年份:
    2023
  • 资助金额:
    $ 3.65万
  • 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
  • 批准号:
    23K05057
  • 财政年份:
    2023
  • 资助金额:
    $ 3.65万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了